KALARIS THERAPEUTICS, INC. Operating Lease Cost
KALARIS THERAPEUTICS, INC. (KLRS) reported Operating Lease Cost of $88.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $88.00K.
- KALARIS THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-03-31 was $88.00K.
- KALARIS THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-12-31 was $88.00K.
- KALARIS THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-09-30 was $29.00K.
- KALARIS THERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $117.00K, a 80.50% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $600.00K, a 93.81% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $9.70M, a 46.97% increase from fiscal 2022.
- KALARIS THERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $6.60M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $88.00K 10-Q · filed 2026-08-11 | $176.00K 10-Q · filed 2026-08-11 | $264.00K derived: sum of 3 quarters · filed 2026-08-11 | $293.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $88.00K 10-Q · filed 2026-05-12 | $176.00K derived: sum of 2 quarters · filed 2026-05-12 | $205.00K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2025-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $117.00K derived: sum of 2 quarters · filed 2026-03-17 | $117.00K 10-K · filed 2026-03-17 | |
| 2025-09-30 | $29.00K 10-Q · filed 2025-11-12 | $29.00K 10-Q · filed 2025-11-12 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | $300.00K derived: sum of 3 quarters · filed 2025-03-07 | $600.00K 10-K · filed 2025-03-07 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $300.00K derived: sum of 2 quarters · filed 2024-11-12 | $600.00K 10-Q · filed 2024-11-12 | $2.70M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-06-30 | $300.00K 10-Q · filed 2024-08-09 | $600.00K 10-Q · filed 2024-08-09 | $2.70M derived: sum of 3 quarters · filed 2025-03-07 | $5.30M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-03-31 | $400.00K 10-Q · filed 2024-05-13 | $2.40M derived: sum of 2 quarters · filed 2025-03-07 | $5.00M derived: sum of 3 quarters · filed 2025-03-07 | $7.60M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $4.60M derived: sum of 2 quarters · filed 2025-03-07 | $7.20M derived: sum of 3 quarters · filed 2025-03-07 | $9.70M 10-K · filed 2025-03-07 |
| 2023-09-30 | $2.60M 10-Q · filed 2024-11-12 | $5.20M derived: sum of 2 quarters · filed 2024-11-12 | $7.70M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $2.60M 10-Q · filed 2024-08-09 | $5.10M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $2.60M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $6.60M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |